(adsbygoogle = window.adsbygoogle || []).push({});
CureVac, whose vaccine comes with easier storage requirements than other mRNA shots, laid out a possible path to salvage its vaccine, emphasizing its utility in people 18 to 60 years old. In that age group, overall efficacy was 53 percent, with much stronger protection against moderate and severe cases of illness. For people in that group, it completely protected against hospitalization and death, and offered 77 percent protection against moderate and severe cases.